Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ND-003 in Healthy Volunteers
NCT06360874Phase 1Enrolling by invitation
- Sponsor
- Shenzhen NewDEL Biotech Co., Ltd.
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments, Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ND-003 in solid tumor, Renal fibrosis, idiopathic pulmonary fibrosis (IPF) and 1 more (10 arms), sponsored by Shenzhen NewDEL Biotech Co., Ltd. Primary endpoint: Adverse Events (AE). Started May 2024; status: enrolling by invitation.
02
Drugs
ND-003
03
Conditions
solid tumorRenal fibrosisidiopathic pulmonary fibrosis (IPF)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06360874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360874.